Hisako Nishimoto, Tadayoshi Kurita, Mikihiro Shimizu, Koji Morita, Yoshiki Nakajima
This study is the first to report 50% and 95% effect-site concentrations (EC50 and EC95 , respectively) of the new short-acting benzodiazepine, remimazolam, for the successful insertion of i-gels with co-administration of fentanyl. Thirty patients (38 ± 5 years old, male/female = 4/26) were randomly assigned into five groups to receive one of five different remimazolam doses (0.1, 0.15, 0.2, 0.25, and 0.3 mg/kg bolus followed by infusion of 1, 1.5, 2, 2.5, and 3 mg/kg/h, respectively, for 10 min), which were designed to maintain a constant effect-site concentration of remimazolam at the time of i-gel insertion...
March 5, 2024: Journal of Clinical Monitoring and Computing